HIV/AIDS, TB and malaria kill 6 million people every year; nearly 2 million deaths are caused by TB.

TB is curable but kills 5000 people every day.

TB is a disease of poverty; virtually all TB deaths are in the developing world, affecting mostly young adults in their most productive years.

TB especially affects the most vulnerable such as the poorest and malnourished.

TB is a leading killer among HIV-infected people with weakened immune systems; a quarter of a million TB deaths are HIV-associated, most of them being in Africa.

Global TB incidence is still growing at 1% a year because of the rapid increase in Africa; intense control efforts are helping incidence fall or stabilize in other regions.

2 billion people, equal to one-third of the world’s total population, are infected with TB bacilli, the microbes that cause TB.

1 in 10 people infected with TB bacilli will become sick with active TB in their lifetime; people with HIV are at a much greater risk.

TB is contagious and spreads through the air; if not treated, each person with active TB infects on average 10 to 15 people every year.

TB is a worldwide pandemic; though the highest rates per capita are in Africa (29% of all TB cases), half of all new cases are in 6 Asian countries (Bangladesh, China, India, Indonesia, Pakistan, the Philippines).

Almost 9 million new TB cases occurred in 2004 and 80% of them in 22 countries.

Multidrug-resistant TB (MDR-TB) is a form of TB that does not respond to the standard drug treatment. MDR-TB is present in virtually all 109 countries recently surveyed by WHO and partners.

450 000 new MDR-TB cases are estimated to occur every year. The highest rates of MDR-TB are in countries of the former Soviet Union and China.

THE TB TARGETS

2015

Millennium Development Goals target to have halted and begun to reverse TB incidence; and associated Stop TB Partnership target of halving prevalence and deaths by 2015 in comparison to 1990.

2005

World Health Assembly targets to detect at least 70% of sputum smear-positive i.e. infectious TB cases (latest data for 2004: 53%) and treat successfully 85% of detected cases (2003: 82%).

THE NEW STOP TB STRATEGY

Pursue high-quality DOTS expansion and enhancement

Address TB/HIV, MDR-TB and other challenges

Contribute to health system strengthening

Engage all care providers

Empower people with TB and communities

Enable and promote research
The Global Plan to STOP TB 2006–2015 will:

- Achieve the Millennium Development Goal to have halted and begun to reverse the incidence of TB by 2015
- Expand access to high-quality TB diagnosis and treatment for all
- Save an additional 14 million lives
- Treat 50 million people for TB
- Put 3 million TB patients coinfected with HIV onto antiretrovirals
- Treat 800 000 people for MDR-TB
- Produce the first new anti-TB drug in 40 years by 2010
- Develop a new vaccine by 2015
- Provide rapid and inexpensive diagnostic tests at the point of care

WHO’s new Stop TB Strategy (see previous page) aims to reach all patients, intensify TB control and ensure the MDG target for 2015 is met. The new strategy is built around the achievements of DOTS, and addresses all new challenges to successful TB control.

DOTS has 5 elements: (i) political commitment with increased and sustained financing; (ii) case detection through quality-assured bacteriology; (iii) standardized treatment with supervision and patient support; (iv) an effective drug supply and management system; (v) monitoring and evaluation system, and impact measurement.

183 countries have adopted DOTS, although nearly one-fifth of the world’s population still has no access to DOTS services.

More than 22 million TB patients have been treated under DOTS since 1995.

The WHO Stop TB Department together with WHO regional and country offices: develops policies, strategies and standards; supports the efforts of WHO Member States; measures progress towards TB targets and assesses national programme performance, financing and impact; and facilitates partnerships, advocacy and communication.

The Stop TB Partnership whose secretariat is housed by WHO, is a network of 500 stakeholders; it has a Coordinating Board and 7 working groups: Advocacy, Communication and Social Mobilization; DOTS Expansion; DOTS-Plus for MDR-TB; TB/HIV; New Drugs; New Diagnostics; New Vaccines.

Full funding of the Global Plan to Stop TB 2006–2015 over the next 10 years will cost US$ 56 billion, and represents a three-fold increase in investment. The estimated funding gap is US$ 31 billion.

The Global Drug Facility, run by the Stop TB Partnership, is expanding access to drugs for DOTS scale up; in just 5 years it has committed over 7 million TB treatments.

Projects managing MDR-TB can apply through the Green Light Committee for access to quality-assured MDR-TB drugs at reduced prices – in some cases by more than 90%. The Committee is operated by WHO and the Stop TB Partnership.

In 2005, 46 African Health Ministers declared TB a regional emergency in Africa; the Regional Director for WHO’s European Region also warned of a TB emergency in Europe.

G8 world leaders are committed to fighting TB. In their 2005 Africa communiqué they pledged to help meet the needs identified by the Stop TB Partnership; meet the financing needs of the Global Fund to Fight AIDS, TB and Malaria; and encourage the development of new drugs and vaccines.

The Stop TB Partnership’s Blueprint for TB Control in Africa 2006–2007 outlined resources and activities required for the region.

In 2006, International Standards for TB Care developed by leading health experts were issued. The International Standards describe a widely accepted level of care that all practitioners should seek in managing patients who have, or are suspected of having, tuberculosis.

The Patients’ Charter for TB Care, also issued in 2006, was created by the TB patient and activist communities. The Charter outlines the rights and responsibilities of people with TB.